vs
Side-by-side financial comparison of Aeluma, Inc. (ALMU) and Atara Biotherapeutics, Inc. (ATRA). Click either name above to swap in a different company.
Atara Biotherapeutics, Inc. is the larger business by last-quarter revenue ($1.6M vs $1.3M, roughly 1.3× Aeluma, Inc.). On growth, Aeluma, Inc. posted the faster year-over-year revenue change (-21.1% vs -95.1%).
Aeluma, Inc. is a U.S.-headquartered technology firm focused on the design, development, and production of high-performance optoelectronic components and semiconductor products. Its core offerings include photonic sensors and laser diodes, serving the LiDAR, 5G/6G communication, industrial sensing, and automotive markets across North America and the Asia-Pacific region.
Atara Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic T-cell immunotherapies for patients with unmet medical needs across oncology, autoimmune disease, and infectious disease indications. It operates primarily in North America, Europe, and Asia-Pacific, partnering with research institutions to advance its novel treatment pipeline.
ALMU vs ATRA — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3M | $1.6M |
| Net Profit | $-1.9M | — |
| Gross Margin | 27.8% | — |
| Operating Margin | -163.6% | — |
| Net Margin | -145.7% | — |
| Revenue YoY | -21.1% | -95.1% |
| Net Profit YoY | 36.0% | 73.2% |
| EPS (diluted) | $-0.11 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.3M | $1.6M | ||
| Q3 25 | $1.4M | $3.5M | ||
| Q2 25 | — | $17.6M | ||
| Q1 25 | — | $98.1M | ||
| Q4 24 | — | $32.8M | ||
| Q3 24 | — | $40.2M | ||
| Q2 24 | — | $28.6M | ||
| Q1 24 | — | $27.4M |
| Q4 25 | $-1.9M | — | ||
| Q3 25 | $-1.5M | $-4.3M | ||
| Q2 25 | — | $2.4M | ||
| Q1 25 | — | $38.0M | ||
| Q4 24 | — | $-12.7M | ||
| Q3 24 | — | $-21.9M | ||
| Q2 24 | — | $-19.0M | ||
| Q1 24 | — | $-31.8M |
| Q4 25 | 27.8% | — | ||
| Q3 25 | 49.4% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -163.6% | — | ||
| Q3 25 | -116.1% | -103.5% | ||
| Q2 25 | — | 18.2% | ||
| Q1 25 | — | 39.5% | ||
| Q4 24 | — | -37.3% | ||
| Q3 24 | — | -54.1% | ||
| Q2 24 | — | -63.7% | ||
| Q1 24 | — | -114.2% |
| Q4 25 | -145.7% | — | ||
| Q3 25 | -107.8% | -124.6% | ||
| Q2 25 | — | 13.6% | ||
| Q1 25 | — | 38.7% | ||
| Q4 24 | — | -38.8% | ||
| Q3 24 | — | -54.5% | ||
| Q2 24 | — | -66.5% | ||
| Q1 24 | — | -116.1% |
| Q4 25 | $-0.11 | — | ||
| Q3 25 | $-0.09 | $-0.32 | ||
| Q2 25 | — | $0.19 | ||
| Q1 25 | — | $3.50 | ||
| Q4 24 | — | $0.27 | ||
| Q3 24 | — | $-2.93 | ||
| Q2 24 | — | $-3.10 | ||
| Q1 24 | — | $-5.65 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $38.6M | $8.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $40.8M | $-38.5M |
| Total Assets | $42.6M | $20.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $38.6M | $8.5M | ||
| Q3 25 | $25.9M | $13.7M | ||
| Q2 25 | — | $22.3M | ||
| Q1 25 | — | $13.8M | ||
| Q4 24 | — | $42.5M | ||
| Q3 24 | — | $67.2M | ||
| Q2 24 | — | $35.3M | ||
| Q1 24 | — | $46.2M |
| Q4 25 | $40.8M | $-38.5M | ||
| Q3 25 | $40.9M | $-36.6M | ||
| Q2 25 | — | $-35.0M | ||
| Q1 25 | — | $-55.1M | ||
| Q4 24 | — | $-97.3M | ||
| Q3 24 | — | $-90.5M | ||
| Q2 24 | — | $-110.9M | ||
| Q1 24 | — | $-98.3M |
| Q4 25 | $42.6M | $20.2M | ||
| Q3 25 | $42.7M | $30.2M | ||
| Q2 25 | — | $36.9M | ||
| Q1 25 | — | $62.0M | ||
| Q4 24 | — | $109.1M | ||
| Q3 24 | — | $142.7M | ||
| Q2 24 | — | $117.3M | ||
| Q1 24 | — | $165.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-251.0K | $-50.9M |
| Free Cash FlowOCF − Capex | $-282.0K | — |
| FCF MarginFCF / Revenue | -22.2% | — |
| Capex IntensityCapex / Revenue | 2.4% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-251.0K | $-50.9M | ||
| Q3 25 | $-815.0K | $-9.8M | ||
| Q2 25 | — | $-7.3M | ||
| Q1 25 | — | $-28.1M | ||
| Q4 24 | — | $-24.5M | ||
| Q3 24 | — | $-4.0M | ||
| Q2 24 | — | $-10.6M | ||
| Q1 24 | — | $-29.6M |
| Q4 25 | $-282.0K | — | ||
| Q3 25 | $-1.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-24.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-10.7M | ||
| Q1 24 | — | $-29.7M |
| Q4 25 | -22.2% | — | ||
| Q3 25 | -74.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -75.0% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -37.3% | ||
| Q1 24 | — | -108.7% |
| Q4 25 | 2.4% | 0.0% | ||
| Q3 25 | 15.2% | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -3.07× | ||
| Q1 25 | — | -0.74× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
